Company intelligence / Profile preview
Tianhe Stem Cell Biotechnologies
Illinois, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Stem Cell Educator Therapy has shown safety and efficacy in international multicenter Phase I/II trials for type 1 diabetes, with lasting metabolic improvements in patients; Phase 2 trials approved by FDA for type 1 diabetes, alopecia areata, and COVID-19.
- Therapeutic areas
- EndocrinologyImmunologyDermatologyInfectious Diseases
- Modalities
- Stem cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CORD:USE
Beyond the preview
Go deeper on Tianhe Stem Cell Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianhe Stem Cell Biotechnologies.